Filing Details

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

SCHEDULE 13G

(Rule 13d-102)

Information to be Included in Statements Filed Pursuant

to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

Pursuant to § 240.13d-2

Under the Securities Exchange Act of 1934

(Amendment No. )

 

 

Therapeutics Acquisition Corp.

(Name of Issuer)

 

 

Class A common stock, $0.0001 par value per share

(Title of Class of Securities)

88339T103

(CUSIP Number)

July 10, 2020

(Date of Event Which Requires Filing of This Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

 

*	The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

CUSIP No. 88339T103		13G		Page 2 of 7 Pages

 

1		Names of Reporting Persons   Bain Capital Life Sciences Fund II, L.P.
2		Check the Appropriate Box if a Member of a Group (a)  ☐        (b)  ☐
3		SEC Use Only
4		Citizenship or Place of Organization   Cayman Islands

Number of Shares Beneficially Owned by Each Reporting Person With				5		Sole Voting Power   0 shares of Class A common stock
				6		Shared Voting Power   891,429 shares of Class A common stock
				7		Sole Dispositive Power   0 shares of Class A common stock
				8		Shared Dispositive Power   891,429 shares of Class A common stock

9		Aggregate Amount Beneficially Owned by Each Reporting Person   891,429 shares of Class A common stock
10		Check if the Aggregate Amount in Row (9) Excludes Certain Shares   ☐
11		Percent of Class Represented by Amount in Row 9   6.3%
12		Type of Reporting Person   PN

CUSIP No. 88339T103		13G		Page 3 of 7 Pages

 

1		Names of Reporting Persons   BCIP Life Sciences Associates, LP
2		Check the Appropriate Box if a Member of a Group (a)  ☐        (b)  ☐
3		SEC Use Only
4		Citizenship or Place of Organization   Delaware

Number of Shares Beneficially Owned by Each Reporting Person With				5		Sole Voting Power   0 shares of Class A common stock
				6		Shared Voting Power   108,571 shares of Class A common stock
				7		Sole Dispositive Power   0 shares of Class A common stock
				8		Shared Dispositive Power   108,571 shares of Class A common stock

9		Aggregate Amount Beneficially Owned by Each Reporting Person   108,571 shares of Class A common stock
10		Check if the Aggregate Amount in Row (9) Excludes Certain Shares   ☐
11		Percent of Class Represented by Amount in Row 9   0.8%
12		Type of Reporting Person   PN

Item 1(a)

Name of Issuer

The name of the issuer to which this filing on Schedule 13G relates is Therapeutics Acquisition Corp. (the Issuer).

 

Item 1(b)

Address of Issuers Principal Executive Offices

The principal executive offices of the Issuer are located at 200 Berkeley Street, 18th Floor, Boston, Massachusetts 02116.

 

Item 2(a)

Name of Person Filing

This Schedule 13G is being filed jointly by Bain Capital Life Sciences Fund II, L.P., a Cayman exempted limited partnership (BCLS II), and BCIP Life Sciences Associates, LP, a Delaware limited partnership (BCIPLS and, together with BCLS II, the Reporting Persons).

Bain Capital Life Sciences Investors, LLC, a Delaware limited liability company (BCLSI), whose managers are Jeffrey Schwartz and Adam Koppel, is the manager of Bain Capital Life Sciences Investors II, LLC, a Cayman limited liability company (BCLSI II), which is the general partner of BCLS II.

Boylston Coinvestors, LLC, a Delaware limited liability company (Boylston), is the general partner of BCIPLS. BCLSI governs the investment strategy and decision-making process with respect to investments held by BCIPLS.

As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by the Reporting Persons.

The Reporting Persons have entered into a Joint Filing Agreement, dated July 20, 2020, pursuant to which the Reporting Persons have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k)(1) promulgated under the Act.

 

Item 2(b)

Address of Principal Business Office or, if None, Residence

The principal business address of each of the Reporting Persons, BCLSI, BCLSI II, Boylston, Mr. Schwartz and Dr. Koppel is 200 Clarendon Street, Boston, MA 02116.

 

Item 2(c)

Citizenship

BCLS II and BCLSI II are each organized under the laws of the Cayman Islands. BCIPLS, BCLSI and Boylston are each organized under the laws of the State of Delaware. Mr. Schwartz and Dr. Koppel are citizens of the United States.

 

Item 2(d)

Title of Class of Securities

The class of securities of the Issuer to which this Schedule 13G relates is Class A common stock, $0.0001 par value per share (Class A common stock).

 

Item 2(e)

CUSIP Number

The CUSIP number of the Class A common stock is 88339T103.

 

Item 3

If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a

(a) ☐		Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b) ☐		Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c) ☐		Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d) ☐		Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e) ☐		An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f) ☐		An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g) ☐		A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h) ☐		A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i) ☐		A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
(j) ☐		A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
(k) ☐		Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

 

Item 4

Ownership

(a) Amount beneficially owned:

As of the date hereof, BCLS II holds 891,429 shares of Class A common stock, representing approximately 6.3% of the Issuers outstanding shares of Class A common stock, and BCIP LS holds 108,571 shares of Class A common stock, representing approximately 0.8% of the Issuers outstanding shares of Class A common stock.

As a result of the foregoing and the relationships described in Item 2(a), the Reporting Persons may be deemed to collectively beneficially own an aggregate of 1,000,000 shares of Class A common stock, representing approximately 7.1% of the Issuers outstanding shares of Class A common stock.

The percentage of the Issuers outstanding shares of Class A common stock held by the Reporting Persons is based on 14,041,400 shares of Class A common stock issued and outstanding immediately following the closing of the Issuers initial public offering and concurrent private placement on July 10, 2020, after giving effect to the exercise in full of the underwriters over-allotment option, as reported by the Issuer in its Prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended, on July 9, 2020.

(b) Percent of class:

See Item 4(a) hereof.

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

0 shares of Class A common stock

(ii) Shared power to vote or to direct the vote:

 

BCLS II

891,429 shares of Class A common stock

 

BCIP LS

108,571 shares of Class A common stock

(iii) Sole power to dispose or to direct the disposition of:

0 shares of Class A common Stock

(iv) Shared power to dispose or to direct the disposition of:

 

BCLS II

891,429 shares of Class A common stock

 

BCIP LS

108,571 shares of Class A common stock

 

Item 5

Ownership of Five Percent or Less of a Class

Not applicable.

 

Item 6

Ownership of More Than Five Percent on Behalf of Another Person

Not applicable.

 

Item 7

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

Not applicable.

 

Item 8

Identification and Classification of Members of the Group

Not applicable.

 

Item 9

Notice of Dissolution of Group

Not applicable.

 

Item 10

Certifications

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURES

After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information in this statement is true, complete and correct.

 

Dated: July 20, 2020				Bain Capital Life Sciences Fund II, L.P.
				By:		Bain Capital Life Sciences Investors II, LLC
						its general partner
				By:		Bain Capital Life Sciences Investors, LLC
						its manager
				By:		/s/ Adam Koppel
						Name:		Adam Koppel
						Title:		Managing Director
				BCIP Life Sciences Associates, LP
				By:		Boylston Coinvestors, LLC
						its general partner
				By:		/s/ Adam Koppel
						Name:		Adam Koppel
						Title:		Authorized Signatory

 

Exhibit A

AGREEMENT REGARDING THE JOINT FILING OF

SCHEDULE 13G

The undersigned hereby agree as follows:

(i) Each of them is individually eligible to use the Schedule 13G to which this Exhibit is attached, and such Schedule 13G is filed on behalf of each of them; and

(ii) Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

 

Dated: July 20, 2020				Bain Capital Life Sciences Fund II, L.P.
				By:		Bain Capital Life Sciences Investors II, LLC
						its general partner
				By:		Bain Capital Life Sciences Investors, LLC
						its manager
				By:		/s/ Adam Koppel
						Name:		Adam Koppel
						Title:		Managing Director
				BCIP Life Sciences Associates, LP
				By:		Boylston Coinvestors, LLC
						its general partner
				By:		/s/ Adam Koppel
						Name:		Adam Koppel
						Title:		Authorized Signatory